Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma's stock price has declined by 37.50% over the past six months. Key events include warrant exchange agreements in August 2025, Q3 2025 earnings report of -$2.2 million, the resignation of CFO Keith Kucinski in November 2025, and a noncompliance notice from the NYSE in January 2026. The company has also faced recent analyst downgrades.

While specific demand seasonality for Matinas BioPharma's products is not explicitly detailed, the broader biotechnology and pharmaceutical industry can exhibit seasonal trends, such as increased demand for flu treatments in winter or allergy medications in spring. The biotech sector's stock performance has also shown seasonality, with periods of strength in late summer and December, and challenging periods during the summer months. Pharmaceutical manufacturers face challenges during warmer months related to temperature control and potential surges in demand for specific medications.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company that develops pharmaceutical products using its Lipid Nanocrystal (LNC) platform technology for targeted drug delivery. Their product candidates include MAT2203, an oral formulation of amphotericin B in Phase 3 trials, and MAT2501, an orally administered formulation of amikacin. The company also has strategic collaborations with the National Institute of Allergy and Infectious Diseases, BioNTech SE, and Genentech Inc.

Matinas BioPharma Holdings, Inc. is based in Bedminster, New Jersey, and primarily operates within the United States market.

Matinas BioPharma's reputation has been influenced by the NYSE noncompliance notice, the resignation of CFO Keith Kucinski, and analyst downgrades from Alliance Global Partners and Maxim, which could negatively impact investor confidence and the company's standing.

Matinas BioPharma Holdings, Inc. has a diverse ownership structure, with institutional investors holding between 0.77% and 5.15% of the stock, insiders owning between 4.49% and 13.11%, and public companies and individual investors holding approximately 84.17%. Major institutional shareholders include Vanguard Group Inc, Geode Capital Management, Llc, and BlackRock, Inc. Jerome D. Jabbour is the individual owning the most shares.